Jefferies Group reissued their hold rating on shares of uniQure NV (NASDAQ:QURE) in a research report sent to investors on Monday. They currently have a $28.00 price objective on the stock, up from their prior price objective of $8.00.

Other equities research analysts have also issued reports about the company. Zacks Investment Research upgraded uniQure NV from a sell rating to a buy rating and set a $8.00 price target for the company in a research report on Thursday, November 17th. HC Wainwright initiated coverage on uniQure NV in a research report on Thursday, August 4th. They issued a buy rating and a $21.00 price target for the company. Leerink Swann restated a positive rating and issued a $27.00 price target on shares of uniQure NV in a research report on Tuesday, August 2nd. Chardan Capital set a $35.00 price target on uniQure NV and gave the company a buy rating in a research report on Thursday, July 28th. Finally, Cowen and Company reiterated a buy rating on shares of uniQure NV in a research report on Thursday, July 28th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $24.70.

Shares of uniQure NV (NASDAQ:QURE) opened at 7.13 on Monday. uniQure NV has a 12 month low of $6.63 and a 12 month high of $22.79. The company’s market capitalization is $179.17 million. The firm’s 50-day moving average price is $7.26 and its 200-day moving average price is $8.64.

A number of hedge funds have recently bought and sold shares of QURE. JPMorgan Chase & Co. boosted its stake in uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock worth $104,000 after buying an additional 5,760 shares in the last quarter. Capital Fund Management S.A. acquired a new stake in uniQure NV during the third quarter worth $111,000. TFS Capital LLC boosted its stake in uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock worth $112,000 after buying an additional 437 shares in the last quarter. Princeton Alpha Management LP acquired a new stake in uniQure NV during the second quarter worth $120,000. Finally, Fox Run Management L.L.C. acquired a new stake in uniQure NV during the second quarter worth $122,000. Institutional investors own 28.99% of the company’s stock.

uniQure NV Company Profile

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.